Abstract
INTRODUCTION
Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p-tau217) in Alzheimer’s disease (AD) remains uncertain.
METHODS
In this multi-cohort study of 2117 individuals, we established baseline plasma p-tau217 thresholds for amyloid-β–positron emission tomography (Aβ-PET) and assessed their longitudinal classification stability and prognostic relevance for AD-related outcomes.
RESULTS
Baseline-defined cutoffs achieved high and sustained accuracy (86%–95%) for Aβ-PET positivity over up to 5 years of follow-up. Longitudinally, most p-tau217–positive individuals remained stable (93%–98%), whereas the intermediate zone group progressed more to positive (44%–78%) than p-tau217–negative individuals (4%–21%). Participants with stable-positive and progress-to-positive p-tau217 profiles more frequently exhibited Aβ abnormalities (90%–100% and 64%–96%, respectively) and experienced accelerated tau accumulation, hippocampal atrophy, and incident dementia compared to those with a stable-negative p-tau217 profile.
DISCUSSION
These findings support the high stability and Aβ-PET classification performance of longitudinal plasma p-tau217 monitoring in AD, providing a scalable tool for risk stratification and disease monitoring.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: | August 30, 2026
Neuro-Dementia